{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T15:17:54Z","timestamp":1787584674920,"version":"build-2736575974"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Comprehensive analysis of clinical evidence for breast cancer adipogenesis with prognosis is lacking. This study aims to consolidate the latest evidence on the relationship between adipogenesis and breast cancer outcomes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Data sources<\/jats:title>\n                <jats:p>: Medline, Web of Science, Embase, Scopus, Clinicaltrials.gov, Cochrane library.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A systematic review was conducted according to the PRISMA guidelines. Studies that reported the correlation between tumor adipogenesis and cancer recurrence or empirical pathological markers were included for meta-analysis. The standard reference for pathological markers determination was set as histopathological examination. The PROSPERO ID was CRD489135.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Eleven studies were included in this systematic review and meta-analysis. Several adipogenesis biomarkers involved in the synthesis, elongation, and catabolism of fatty acids, such as FASN, Spot 14, pS6K1, lipin-1, PLIN2, Elovl6, and PPAR\u03b3, were identified as the potential biomarkers for predicting outcomes. Through meta-analysis, the predictive value of adipogenesis biomarkers for 5-year recurrence rate was calculated, with a pooled predictive risk ratio of 2.19 (95% CI: 1.11\u20134.34). In terms of empirical pathological markers, a negative correlation between adipogenesis biomarkers and ki-67 was observed (RR: 0.69, 95% CI: 0.61\u20130.79). However, no significant correlation was found between the adipogenesis and ER, PR, HER2, or p53 positivity.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Biomarker of adipogenesis in breast cancer is a significant predictor of long-term recurrence, and this prediction is independent of HR, HER2, and ki-67. The diverse roles of adipogenesis in different breast cancer subtypes highlight the need for further research to uncover specific biomarkers that can used for diagnosis and prediction.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Protocol registration<\/jats:title>\n                <jats:p><jats:italic>PROSPERO ID: CRD489135<\/jats:italic>.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-024-12931-1","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T14:04:13Z","timestamp":1727445853000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Adipogenesis biomarkers as the independent predictive factors for breast cancer recurrence: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"24","author":[{"given":"Shihang","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sze Keong","family":"Tey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ava","family":"Kwong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,27]]},"reference":[{"key":"12931_CR1","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1016\/j.cell.2023.01.040","volume":"186","author":"E Nolan","year":"2023","unstructured":"Nolan E, Lindeman GJ, Visvader JE. Deciphering breast cancer: from biology to the clinic. Cell. 2023;186:1708\u201328. https:\/\/doi.org\/10.1016\/j.cell.2023.01.040.","journal-title":"Cell"},{"key":"12931_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.plipres.2017.11.002","volume":"69","author":"J Choi","year":"2018","unstructured":"Choi J, Cha YJ, Koo JS. Adipocyte biology in breast cancer: from silent bystander to active facilitator. Prog Lipid Res. 2018;69:11\u201320.","journal-title":"Prog Lipid Res"},{"key":"12931_CR3","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1186\/s12885-018-4170-7","volume":"18","author":"X An","year":"2018","unstructured":"An X, et al. The prognostic significance of topoisomerase II alpha protein in early stage luminal breast cancer. BMC Cancer. 2018;18:331. https:\/\/doi.org\/10.1186\/s12885-018-4170-7.","journal-title":"BMC Cancer"},{"key":"12931_CR4","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s10549-011-1432-3","volume":"129","author":"Y Liu","year":"2011","unstructured":"Liu Y, et al. The association between vascular endothelial growth factor expression in invasive breast cancer and survival varies with intrinsic subtypes and use of adjuvant systemic therapy: results from the nurses\u2019 Health Study. Breast Cancer Res Treat. 2011;129:175\u201384. https:\/\/doi.org\/10.1007\/s10549-011-1432-3.","journal-title":"Breast Cancer Res Treat"},{"key":"12931_CR5","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s10549-013-2563-5","volume":"139","author":"XL Xu","year":"2013","unstructured":"Xu XL, et al. The impact of cyclin D1 overexpression on the prognosis of ER-positive breast cancers: a meta-analysis. Breast Cancer Res Treat. 2013;139:329\u201339. https:\/\/doi.org\/10.1007\/s10549-013-2563-5.","journal-title":"Breast Cancer Res Treat"},{"key":"12931_CR6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1200\/JCO.2010.33.0068","volume":"30","author":"PJ Goodwin","year":"2012","unstructured":"Goodwin PJ, et al. Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an international prospective breast Cancer Family Registry population-based cohort study. J Clin Oncol. 2012;30:19\u201326. https:\/\/doi.org\/10.1200\/JCO.2010.33.0068.","journal-title":"J Clin Oncol"},{"key":"12931_CR7","doi-asserted-by":"publisher","first-page":"93","DOI":"10.21037\/atm-21-6924","volume":"10","author":"Y Chen","year":"2022","unstructured":"Chen Y, et al. Impact of hormone receptor, HER2, and Ki-67 status conversions on survival after neoadjuvant chemotherapy in breast cancer patients: a retrospective study. Ann Transl Med. 2022;10:93. https:\/\/doi.org\/10.21037\/atm-21-6924.","journal-title":"Ann Transl Med"},{"key":"12931_CR8","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1038\/s41379-019-0270-4","volume":"32","author":"M Abubakar","year":"2019","unstructured":"Abubakar M, et al. Combined quantitative measures of ER, PR, HER2, and KI67 provide more prognostic information than categorical combinations in luminal breast cancer. Mod Pathol. 2019;32:1244\u201356. https:\/\/doi.org\/10.1038\/s41379-019-0270-4.","journal-title":"Mod Pathol"},{"key":"12931_CR9","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1002\/dvdy.10065","volume":"223","author":"C Couldrey","year":"2002","unstructured":"Couldrey C, et al. Adipose tissue: a vital in vivo role in mammary gland development but not differentiation. Dev Dyn. 2002;223:459\u201368. https:\/\/doi.org\/10.1002\/dvdy.10065.","journal-title":"Dev Dyn"},{"key":"12931_CR10","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13045-019-0778-6","volume":"12","author":"Q Wu","year":"2019","unstructured":"Wu Q, et al. Cancer-associated adipocytes: key players in breast cancer progression. J Hematol Oncol. 2019;12:95. https:\/\/doi.org\/10.1186\/s13045-019-0778-6.","journal-title":"J Hematol Oncol"},{"key":"12931_CR11","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1023\/a:1018786604818","volume":"3","author":"MC Neville","year":"1998","unstructured":"Neville MC, Medina D, Monks J, Hovey RC. The mammary fat pad. J Mammary Gland Biol Neoplasia. 1998;3:109\u201316. https:\/\/doi.org\/10.1023\/a:1018786604818.","journal-title":"J Mammary Gland Biol Neoplasia"},{"key":"12931_CR12","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s10549-015-3348-9","volume":"150","author":"R Abduljabbar","year":"2015","unstructured":"Abduljabbar R, et al. Prognostic and biological significance of peroxisome proliferator-activated receptor-gamma in luminal breast cancer. Breast Cancer Res Treat. 2015;150:511\u201322. https:\/\/doi.org\/10.1007\/s10549-015-3348-9.","journal-title":"Breast Cancer Res Treat"},{"key":"12931_CR13","doi-asserted-by":"publisher","first-page":"12541","DOI":"10.1038\/s41598-021-91897-7","volume":"11","author":"M Oshi","year":"2021","unstructured":"Oshi M, et al. Adipogenesis in triple-negative breast cancer is associated with unfavorable tumor immune microenvironment and with worse survival. Sci Rep. 2021;11:12541. https:\/\/doi.org\/10.1038\/s41598-021-91897-7.","journal-title":"Sci Rep"},{"key":"12931_CR14","doi-asserted-by":"publisher","unstructured":"Song L, et al. Proto-oncogene Src links lipogenesis via lipin-1 to breast cancer malignancy. Nat Commun. 2020;11(1):5842. https:\/\/doi.org\/10.1038\/s41467-020-19694-w.","DOI":"10.1038\/s41467-020-19694-w"},{"key":"12931_CR15","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1126\/science.1067431","volume":"296","author":"BS Wiseman","year":"2002","unstructured":"Wiseman BS, Werb Z. Stromal effects on mammary gland development and breast cancer. Science. 2002;296:1046\u20139. https:\/\/doi.org\/10.1126\/science.1067431.","journal-title":"Science"},{"key":"12931_CR16","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.1242\/jcs.02438","volume":"118","author":"S Jansen","year":"2005","unstructured":"Jansen S, et al. Proteolytic maturation and activation of autotaxin (NPP2), a secreted metastasis-enhancing lysophospholipase D. J Cell Sci. 2005;118:3081\u20139. https:\/\/doi.org\/10.1242\/jcs.02438.","journal-title":"J Cell Sci"},{"key":"12931_CR17","doi-asserted-by":"publisher","first-page":"18923","DOI":"10.1038\/srep18923","volume":"6","author":"JO Lee","year":"2016","unstructured":"Lee JO, et al. Resistin, a fat-derived secretory factor, promotes metastasis of MDA-MB-231 human breast cancer cells through ERM activation. Sci Rep. 2016;6:18923. https:\/\/doi.org\/10.1038\/srep18923.","journal-title":"Sci Rep"},{"key":"12931_CR18","doi-asserted-by":"publisher","unstructured":"Strong AL, et al. Leptin produced by obese adipose stromal\/stem cells enhances proliferation and metastasis of estrogen receptor positive breast cancers. Breast Cancer Res. 2015;17. https:\/\/doi.org\/10.1186\/s13058-015-0622-z.","DOI":"10.1186\/s13058-015-0622-z"},{"key":"12931_CR19","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1158\/2159-8290.CD-22-0200","volume":"12","author":"M Anurag","year":"2022","unstructured":"Anurag M, et al. Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-negative breast Cancer. Cancer Discov. 2022;12:2586\u2013605. https:\/\/doi.org\/10.1158\/2159-8290.CD-22-0200.","journal-title":"Cancer Discov"},{"issue":"1","key":"12931_CR20","doi-asserted-by":"publisher","first-page":"10","DOI":"10.4048\/jbc.2020.23.e5","volume":"23","author":"J Choi","year":"2020","unstructured":"Choi J, et al. Predicting the benefit of adjuvant aromatase inhibitor therapy in postmenopausal breast cancer patients with phosphorylated s6k1 expression status. J Breast Cancer. 2020;23(1):10\u20139.","journal-title":"J Breast Cancer"},{"key":"12931_CR21","doi-asserted-by":"publisher","unstructured":"Duong MN, et al. Adipose cells promote resistance of breast cancer cells to trastuzumab-mediated antibody-dependent cellular cytotoxicity. Breast Cancer Res. 2015;17. https:\/\/doi.org\/10.1186\/s13058-015-0569-0.","DOI":"10.1186\/s13058-015-0569-0"},{"key":"12931_CR22","doi-asserted-by":"publisher","first-page":"32576","DOI":"10.18632\/oncotarget.15936","volume":"8","author":"YF Cui","year":"2017","unstructured":"Cui YF, et al. NADPH accumulation is responsible for apoptosis in breast cancer cells induced by fatty acid synthase inhibition. Oncotarget. 2017;8:32576\u201385. https:\/\/doi.org\/10.18632\/oncotarget.15936.","journal-title":"Oncotarget"},{"key":"12931_CR23","doi-asserted-by":"publisher","first-page":"5835","DOI":"10.1002\/jcp.29523","volume":"235","author":"N Dinarvand","year":"2020","unstructured":"Dinarvand N, et al. Expression and clinicopathological significance of lipin-1 in human breast cancer and its association with p53 tumor suppressor gene. J Cell Physiol. 2020;235:5835\u201346. https:\/\/doi.org\/10.1002\/jcp.29523.","journal-title":"J Cell Physiol"},{"key":"12931_CR24","doi-asserted-by":"publisher","first-page":"207","DOI":"10.3892\/ol.2016.4587","volume":"12","author":"YH Feng","year":"2016","unstructured":"Feng YH, et al. Elovl6 is a poor prognostic predictor in breast cancer. Oncol Lett. 2016;12:207\u201312. https:\/\/doi.org\/10.3892\/ol.2016.4587.","journal-title":"Oncol Lett"},{"issue":"8","key":"12931_CR25","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1158\/0008-5472.CAN-15-1646","volume":"76","author":"KS Lucenay","year":"2016","unstructured":"Lucenay KS, et al. Cyclin e associates with the lipogenic enzyme ATP-citrate lyase to enable malignant growth of breast cancer cells. Cancer Res. 2016;76(8):2406\u201318.","journal-title":"Cancer Res"},{"issue":"7","key":"12931_CR26","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1530\/EC-19-0101","volume":"8","author":"CS Park","year":"2019","unstructured":"Park CS, et al. pS6K1 as an efficacy marker of gnrh agonist with premenopausal breast cancer. Endocr Connections. 2019;8(7):863\u20139.","journal-title":"Endocr Connections"},{"key":"12931_CR27","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s10549-005-9154-z","volume":"98","author":"WA Wells","year":"2006","unstructured":"Wells WA, et al. Expression of Spot 14 (THRSP) predicts disease free survival in invasive breast cancer: immunohistochemical analysis of a new molecular marker. Breast Cancer Res Treat. 2006;98:231\u201340. https:\/\/doi.org\/10.1007\/s10549-005-9154-z.","journal-title":"Breast Cancer Res Treat"},{"key":"12931_CR28","doi-asserted-by":"publisher","unstructured":"Yoshikawa K, et al. Association between fatty acid synthase and adipophilin expression in triple-negative breast cancer. Biomed Rep. 2022;16. https:\/\/doi.org\/10.3892\/mco.2022.2513.","DOI":"10.3892\/mco.2022.2513"},{"key":"12931_CR29","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1074\/mcp.M400221-MCP200","volume":"4","author":"D Zhang","year":"2005","unstructured":"Zhang D, et al. Proteomic study reveals that proteins involved in metabolic and detoxification pathways are highly expressed in HER-2\/neu-positive breast cancer. Mol Cell Proteom. 2005;4:1686\u201396. https:\/\/doi.org\/10.1074\/mcp.M400221-MCP200.","journal-title":"Mol Cell Proteom"},{"key":"12931_CR30","first-page":"27","volume":"13","author":"G Medes","year":"1953","unstructured":"Medes G, Thomas A, Weinhouse S. Metabolism of neoplastic tissue. IV. A study of lipid synthesis in neoplastic tissue slices in vitro. Cancer Res. 1953;13:27\u20139.","journal-title":"Cancer Res"},{"key":"12931_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.20517\/cdr.2019.100","volume":"3","author":"WW Feng","year":"2020","unstructured":"Feng WW, Kurokawa M. Lipid metabolic reprogramming as an emerging mechanism of resistance to kinase inhibitors in breast cancer. Cancer Drug Resist. 2020;3:1\u201317. https:\/\/doi.org\/10.20517\/cdr.2019.100.","journal-title":"Cancer Drug Resist"},{"key":"12931_CR32","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/s0899-9007(99)00266-x","volume":"16","author":"FP Kuhajda","year":"2000","unstructured":"Kuhajda FP. Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology. Nutrition. 2000;16:202\u20138. https:\/\/doi.org\/10.1016\/s0899-9007(99)00266-x.","journal-title":"Nutrition"},{"key":"12931_CR33","doi-asserted-by":"publisher","first-page":"1153076","DOI":"10.3389\/fonc.2023.1153076","volume":"13","author":"B Liu","year":"2023","unstructured":"Liu B, et al. Prognostic and clinicopathological significance of fatty acid synthase in breast cancer: a systematic review and meta-analysis. Front Oncol. 2023;13:1153076. https:\/\/doi.org\/10.3389\/fonc.2023.1153076.","journal-title":"Front Oncol"},{"key":"12931_CR34","doi-asserted-by":"publisher","first-page":"21436","DOI":"10.1002\/jcp.28776","volume":"234","author":"YX Wang","year":"2019","unstructured":"Wang YX, et al. Friend or foe: multiple roles of adipose tissue in cancer formation and progression. J Cell Physiol. 2019;234:21436\u201349. https:\/\/doi.org\/10.1002\/jcp.28776.","journal-title":"J Cell Physiol"},{"key":"12931_CR35","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1097\/01.mco.0000232894.28674.30","volume":"9","author":"JV Swinnen","year":"2006","unstructured":"Swinnen JV, Brusselmans K, Verhoeven G. Increased lipogenesis in cancer cells: new players, novel targets. Curr Opin Clin Nutr Metab Care. 2006;9:358\u201365. https:\/\/doi.org\/10.1097\/01.mco.0000232894.28674.30.","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"12931_CR36","doi-asserted-by":"publisher","first-page":"598626","DOI":"10.3389\/fonc.2020.598626","volume":"10","author":"A Naik","year":"2020","unstructured":"Naik A, Decock J. Lactate Metabolism and Immune Modulation in breast Cancer: a focused review on Triple negative breast tumors. Front Oncol. 2020;10:598626. https:\/\/doi.org\/10.3389\/fonc.2020.598626.","journal-title":"Front Oncol"},{"key":"12931_CR37","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.ejca.2019.09.002","volume":"121","author":"AS Dias","year":"2019","unstructured":"Dias AS, Almeida CR, Helguero LA, Duarte IF. Metabolic crosstalk in the breast cancer microenvironment. Eur J Cancer. 2019;121:154\u201371. https:\/\/doi.org\/10.1016\/j.ejca.2019.09.002.","journal-title":"Eur J Cancer"},{"key":"12931_CR38","first-page":"132","volume":"63","author":"C Kumar-Sinha","year":"2003","unstructured":"Kumar-Sinha C, Ignatoski KW, Lippman ME, Ethier SP, Chinnaiyan AM. Transcriptome analysis of HER2 reveals a molecular connection to fatty acid synthesis. Cancer Res. 2003;63:132\u20139.","journal-title":"Cancer Res"},{"key":"12931_CR39","doi-asserted-by":"publisher","first-page":"R96","DOI":"10.1186\/bcr2777","volume":"12","author":"Q Jin","year":"2010","unstructured":"Jin Q, et al. Fatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast cancer cells. Breast Cancer Res. 2010;12:R96. https:\/\/doi.org\/10.1186\/bcr2777.","journal-title":"Breast Cancer Res"},{"key":"12931_CR40","doi-asserted-by":"publisher","unstructured":"Gandhi S, Oshi M, Murthy V, Repasky EA, Takabe K. Enhanced thermogenesis in Triple-negative breast Cancer is Associated with Pro-tumor Immune Microenvironment. Cancers (Basel). 2021;13. https:\/\/doi.org\/10.3390\/cancers13112559.","DOI":"10.3390\/cancers13112559"},{"key":"12931_CR41","doi-asserted-by":"publisher","first-page":"74391","DOI":"10.18632\/oncotarget.20152","volume":"8","author":"A Giro-Perafita","year":"2017","unstructured":"Giro-Perafita A, et al. Fatty acid synthase expression and its association with clinico-histopathological features in triple-negative breast cancer. Oncotarget. 2017;8:74391\u2013405. https:\/\/doi.org\/10.18632\/oncotarget.20152.","journal-title":"Oncotarget"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12931-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-024-12931-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12931-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T14:05:34Z","timestamp":1727445934000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-024-12931-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,27]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["12931"],"URL":"https:\/\/doi.org\/10.1186\/s12885-024-12931-1","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,27]]},"assertion":[{"value":"17 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1181"}}